ArticleDiagnostic cytopathology2026
Extended High-Risk HPV Genotyping With BD Onclarity Enhances Anal Cancer Screening Among High-Risk Populations: A Cross-Sectional Study.
Article in Diagnostic cytopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnal cancer rates are rising among women, immunocompromised individuals, and Men who have sex with Men (MSM), independent of HIV status. While high-resolution anoscopy remains the diagnostic standard, limited access has increased interest in alternative screening. HPV testing now complements or replaces cytology in cervical cancer prevention, but evidence for anal screening, especially using extended genotyping platforms like BD Onclarity, remains limited.
methodsThis single center cross-sectional study enrolled high-risk individuals undergoing anal cancer screening from May 2024 to May 2025. Anal cytology and high-risk HPV (HR-HPV) DNA testing were performed using the BD Onclarity assay on the BD COR system. Demographics, cytology results, HRHPV genotypes, and available histopathology were analyzed.
resultsAmong 117 high-risk participants (median age 42; 106 males, 8 females, 3 transgender women), 74.3% were -HIV positive, predominantly MSM-. Abnormal cytology occurred in 41% of cases including ASC-US (n = 29; 60.4%), LSIL (n = 16; 33.3%), ASC-H (n = 2; 4.1%), and HSIL (n = 1; 2.1%). Valid BD Onclarity results were available for 104 individuals, with 61.5% testing HR-HPV positive. Non-16/18 HR-HPV types were most common overall, while HPV16 predominated in abnormal cytology cases. Twelve individuals underwent biopsy, revealing no dysplasia (n = 2), AIN1 (n = 5), AIN2 (n = 1), and AIN3 (n = 4).
conclusionsExtended HR-HPV genotyping using the BD Onclarity assay demonstrated a high prevalence of HR-HPV in this high-risk population, with multiple genotype infections commonly observed. While non-HPV16/18 genotypes predominated overall, HPV16 was more frequently associated with abnormal cytologic and high-grade histologic findings. Given the limited number of biopsy-confirmed high-grade lesions, these associations should be interpreted as descriptive and hypothesis-generating. Cytology remains central to anal cancer screening, with extended HPV genotyping serving as a complementary adjunct rather than a standalone stratification tool. Larger longitudinal studies with systematic histopathologic follow-up are needed to clarify the clinical significance of extended HPV genotyping in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.